Citations

Showing 10 of 108083 citations.

Young woman with segmental colitis
Anderson, Bradley W., Sweetser, Seth , Imam, Zaid

Mayo Clinic

Gut | September 12, 2017 | Volume: 67 | Issue: 8 | Pages: 1399-1474

10.1136/gutjnl-2017-315122 | PMID 28899985 Get It

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup
Labbé, David P. , Sweeney, Christopher J. , Galbo, Phillip M. , Wadosky, Kristine M. , Ku, Sheng‐Yu , Sjöström, Martin , Alshalalfa, Mohammed , Erho, Nicholas , Karnes, R. Jeffrey , Schaeffer, Edward M. , Jenkins, Robert B. , Ross, Ashley E. , Bowden, Michaela , Huang, Ying , Gray, Kathryn P. , Feng, Felix Y. , Spratt, Daniel E. , Goodrich, David W. , Ellis, Leigh , Spratt, Daniel E , Sweeney, Christopher , Brown, Myles , Rosario, Spencer R. , Davicioni, Elai , Den, Robert B. , Eng, Kevin H.

Mayo Clinic

Clinical Cancer Research | September 12, 2017 | Volume: 23 | Issue: 22 | Pages: 7072-7083

10.1158/1078-0432.ccr-17-0413 | PMID 28899973 Get It

Abstract Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer–associated mortality. Recent gene expression profiling has proven successful in predicting the outcome of prostate cancer patients; however, they have yet to provide targeted therapy approaches that could inhibit a patient's progression to metastatic disease. Experimental Design: We have interrogated a total of seven primary prostate cancer cohorts (n = 1,900), two metastatic castration-resistant prostate cancer datasets (n = 293), and one prospective cohort (n = 1,385) to assess the impact of TOP2A and EZH2 expression on prostate cancer cellular program and patient outcomes. We also performed IHC staining for TOP2A and EZH2 in a cohort of primary prostate cancer patients (n = 89) with known outcome. Finally, we explored the therapeutic potential of a combination therapy targeting both TOP2A and EZH2 using novel prostate cancer–derived murine cell lines. Results: We demonstrate by genome-wide analysis of independent primary and metastatic prostate cancer datasets that concurrent TOP2A and EZH2 mRNA and protein upregulation selected for a subgroup of primary and metastatic patients with more aggressive disease and notable overlap of genes involved in mitotic regulation. Importantly, TOP2A and EZH2 in prostate cancer cells act as key driving oncogenes, a fact highlighted by sensitivity to combination-targeted therapy. Conclusions: Overall, our data support further assessment of TOP2A and EZH2 as biomarkers for early identification of patients with increased metastatic potential that may benefit from adjuvant or neoadjuvant targeted therapy approaches. Clin Cancer Res; 23(22); 7072–83. ©2017 AACR.
MELD Stratified Outcomes Among Recipients With Diabetes or Hypertension
Hasanin, Mohsen, Kaif, Mohamed, Wiesner, Russell W., Kuo, Yong‐Fang , Singal, Ashwani K.

Mayo Clinic

Journal of Clinical Gastroenterology | September 12, 2017 | Volume: 52 | Issue: 1 | Pages: 67-72

10.1097/mcg.0000000000000818 | PMID 28906426 Get It

Background and Aim: Data are scanty on allocating simultaneous liver kidney (SLK) based on model for end-stage disease (MELD) score. Diabetes mellitus (DM) and hypertension (HTN) are frequent in cirrhosis patients. We analyzed transplant recipients with DM and/or HTN to compare MELD-based outcomes of SLK to liver transplantation alone (LTA). Materials and Methods: Of 13,584 first deceased donor liver transplantation among patients with DM and/or HTN (1530 or 11.2% SLK), MELD score predicted SLK [1.02 (1.01-1.03)]. SLK was beneficial for 5-year patient survival at MELD score ≥43 (78.6% vs. 62.6%, P=0.017), but not at MELD score <29 (74.8% vs. 76.2%, P=0.63). Among 11,405 recipients (976 SLK) at MELD score <29, SLK (n=816) was beneficial compared with 706 LTA [75% vs. 64%, P<0.001; 0.71 (0.55-0.91)] at serum creatinine (SC) ≥2 but not at SC<2 [73% vs. 76%, P=0.32; 0.85 (0.60-1.2)]. Among patients with MELD score 29 to 42, SLK (n=484) and LTA (n=1403) had similar survival [69% vs. 69%, P=0.58; 0.9 (0.7-1.5)]. Among patients with MELD score ≥43, SLK (n=70) was associated with 35% improved patient survival at 5 years compared with 222 LTA [0.65 (0.46-0.93)]. Conclusions: Among patients with DM and/or HTN, SLK is useful at: (a) MELD score <29 and SC≥2 and (b) MELD score ≥43. Prospective studies are needed to confirm these findings as basis to optimize use of SLK.
Association of midlife lipids with 20‐year cognitive change: A cohort study
Sharrett, A. Richey, Bandeen‐Roche, Karen , Ballantyne, Christie M. , Pokharel, Yashashwi , Michos, Erin D. , Penman, Alan D. , Ballantyne, Christie M , Michos, Erin D , Power, Melinda C. , Rawlings, Andreea M. , Coresh, Josef , Alonso, Álvaro , Knopman, David S. , Mosley, Thomas H. , Gottesman, Rebecca F.

Mayo Clinic

Alzheimer's & Dementia | September 12, 2017 | Volume: 14 | Issue: 2 | Pages: 167-177

10.1016/j.jalz.2017.07.757 | PMID 28916238 Get It

AbstractIntroductionExisting studies predominantly consider the association of late‐life lipid levels and subsequent cognitive change. However, midlife rather than late‐life risk factors are often most relevant to cognitive health.MethodsWe quantified the association between measured serum lipids in midlife and subsequent 20‐year change in performance on three cognitive tests in 13,997 participants of the Atherosclerosis Risk in Communities study.ResultsElevated total cholesterol, low‐density lipoprotein cholesterol, and triglycerides were associated with greater 20‐year decline on a test of executive function, sustained attention, and processing speed. Higher total cholesterol and triglycerides were also associated with greater 20‐year decline in memory scores and a measure summarizing performance on all three tests. High‐density lipoprotein cholesterol was not associated with cognitive change. Results were materially unchanged in sensitivity analyses addressing informative missingness.DiscussionElevated total cholesterol, low‐density lipoprotein cholesterol, and triglycerides in midlife were associated with greater 20‐year cognitive decline.
Safety and efficacy of coaxial lumen-apposing metal stents in the management of refractory gastrointestinal luminal strictures: a multicenter study
Heffley, Jason D. , Dayyeh, Barham Abu, Nieto, José , Sawas, Tarek , Zaghlol, Raja , Buttar, Navtej , Topazian, Mark , Song, Louis Wong Kee, Levy, Michael J. , Keilin, Steve, Cai, Qiang , Bazerbachi, Fateh , Abu Dayyeh, Barham K, Vargas, Eric J. , Buttar, Navtej S, Wong Kee Song, Louis M, Levy, Michael J. , Willingham, Field F.

Mayo Clinic

Endoscopy International Open | September 12, 2017 | Volume: 05 | Issue: 09 | Pages: E861-E867

10.1055/s-0043-114665 | PMID 28924591 Get It

Abstract Background and aims Benign gastrointestinal (GI) strictures are often refractory to standard endoscopic interventions. Fully covered coaxial lumen-apposing metal stents (LAMS) have emerged as a novel therapy for these strictures. The aim of this study was to evaluate the safety and efficacy of LAMS for refractory GI strictures. Patients and methods A retrospective analysis was performed for patients who underwent LAMS placement for benign luminal strictures in three US centers between January 2014 and December 2016. The primary outcomes were technical success and initial clinical success of LAMS placement. Secondary outcomes were stent migration, rate of re-intervention, and adverse events. Results A total of 49 patients underwent 56 LAMS placement procedures. Previous treatment had failed in 39 patients (79.6 %), and anastomotic strictures were the indication in 77.6 % (38/49), with the most common site being gastrojejunal (34.7 % [17/49]). Technical success was achieved in all procedures and initial clinical success was achieved in 96.4 % of all procedures (54/56). Patient initial clinical success was 95.9 % (47/49). Stent migration occurred in 17.9 % of procedures, and was more likely to occur at sites in the lower GI tract (P = 0.02). The mean stent dwell time was 100.6 days, and the mean follow-up was 169.8 days. Minor adverse events, not requiring hospitalization, occurred in 33.9 % of procedures, including subsequent stricture progression (10.7 %). In cases where LAMS were removed, mean follow-up time was 102.2 days. The re-intervention rate was 75 % at 300 days follow-up after stent removal. Of the LAMS placed at anastomotic strictures, 36.4 % required re-intervention, with approximately two-thirds of these re-interventions requiring placement of a new stent or surgery. Conclusion LAMS placement was successful for the management of refractory GI strictures, with good technical and initial clinical success rates. However, re-intervention rates after LAMS removal were high, and many strictures were not resolved by an extended period of stenting with these coaxial stents. LAMS placement offers additional therapeutic options and in selected cases might be considered a destination therapy for patients with recalcitrant benign strictures.
Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11 C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging
Nehra, Avinash , Haloi, Rimki , Mynderse, Lance A. , Lowe, Val J. , Quevedo, J. Fernando , Johnson, Geoffrey B. , Kwon, Eugene D., Karnes, R. Jeffrey , Parker, William P. , Davis, Brian J. , Johnson, Geoffrey B , Park, Sean S.

Mayo Clinic

Journal of Urology | September 12, 2017 | Volume: 199 | Issue: 3 | Pages: 726-733

10.1016/j.juro.2017.09.033 | PMID 28916273 Get It

Faculty Opinions recommendation of Targeting cellular senescence prevents age-related bone loss in mice.
Evans, Christopher H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 12, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.729069932.793536412 Get It

Sphingolipids in Alzheimer’s Disease and Related Disorders
Martinez, Pilar Martinez, Mielke, Michelle M. , Mielke, Michelle M

Mayo Clinic

Journal of Alzheimer's Disease | September 12, 2017 | Volume: 60 | Issue: 3 | Pages: 753-756

10.3233/jad-170735 | PMID 28922162 Get It

Preliminary results of tissue‐engineered injection laryngoplasty material in a rabbit model
Oldenburg, Michael , Ekbom, Dale C. , Marina, Serban San, Voss, Steve, Chen, Tiffany , García, Joaquín J. , Janus, J.R., Oldenburg, Michael S , San Marina, Serban, Garcia, Joaquin, Janus, Jeffery R

Mayo Clinic

The Laryngoscope | September 12, 2017 | Volume: 128 | Issue: 1 | Pages: 160-167

10.1002/lary.26849 | PMID 28895165 Get It

Objectives/HypothesisDesign and test a novel biomaterial for injection laryngoplasty aimed to increase the duration of effectiveness of micronized acellular dermis.Study DesignAnimal model.MethodsInjection laryngoplasty was performed in three groups (n = 5) of New Zealand White rabbits. Acellular dermis was either used alone as a control (group 1), was combined with undifferentiated stem cells (group 2), or with predifferentiated chondrocytic cells (group 3). Groups 2 and 3 were supplemented with growth factors. Animals were sacrificed 4 and 12 weeks after laryngoplasty and histologic analysis was completed. The major outcome measure was volume of tissue remaining.ResultsAfter 4 weeks, the mean volume of tissue remaining was 341 ± 89 mm3, 295 ± 102 mm3, and 133 ± 15 mm3, for groups 1 to 3, respectively. At the 12‐week time point, volumes were 62 ± 62 mm3, 235 ± 35 mm3, and 107 ± 99 mm3. After 12 weeks, there was a significantly higher volume in group 2 compared to group 1 or 3 (P = .01, P = .04). Volumes between week 4 and week 12 were significantly lower in group 1 (P = .02), but not significantly different for groups 2 and 3 (P = .38, P = .74). Histologic evaluation revealed a robust lymphocytic infiltration in all cases as well as morphologic and immunophenotypic features suggestive of chondrogenic differentiation in a single animal.ConclusionsMicronized acellular dermis combined with stem cells and growth factors showed significantly less resorption 12 weeks after injection laryngoplasty compared to micronized acellular dermis alone. Groups using novel tissue‐engineered biomaterial showed a lower resorption rate over time compared with acellular dermis alone.Level of EvidenceNA. Laryngoscope, 128:160–167, 2018
Undiagnosed Partial Ornithine Transcarbamylase Deficiency Presenting Postoperatively as Agitated Delirium
Cannistraro, Rocco J., Goldstein, Eric , Atwal, Paldeep S , Meschia, James F.

Mayo Clinic

The Neurohospitalist | September 12, 2017 | Volume: 8 | Issue: 2 | Pages: 82-85

10.1177/1941874417729983 | PMID 29623158 Get It

Partial ornithine transcarbamylase deficiency (pOTCD), an enzymatic defect within the urea cycle, is an increasingly recognized etiology for hyperammonemia of unclear source following a stressor within female adults. Here we present a case of newly diagnosed pOTCD following a systemic stressor and prolonged hospitalization course. From a neurological perspective, prompt recognition provided the patient with a swift and near complete recovery. We briefly review the pertinent literature pertaining to this genetically based condition including historical context and current therapeutic approaches. Given the potential morbidity of prolonged hyperammonemia, neurohospitalists need to be aware of partial ornithine transcarbamylase as an entity.